Athersys (OTCPK:ATHX.Q) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ATHX.Q Overzicht aandelen

Athersys, Inc., een biotechnologiebedrijf, richt zich op onderzoeks- en ontwikkelingsactiviteiten op het gebied van regeneratieve geneeskunde.

Over het bedrijf

ATHX.Q fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Earnings have declined by 12.5% per year over past 5 years

Does not have a meaningful market cap ($6K)

Negative shareholders equity

Shareholders have been substantially diluted in the past year

+ 3 meer risico's

Athersys, Inc. Concurrenten

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

ObsEva

OTCPK:OBSE.F

US$11.7k

Mymetics

OTCPK:MYMX

US$151.0

Comera Life Sciences Holdings

OTCPK:CMRA

US$30.0

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Athersys
Historische aandelenkoersen
Huidige aandelenkoers	US$0.000001
52 Week Hoogtepunt	US$0.46
52 Week Laag	US$0.000001
Bèta	-1.23
11 maand verandering	0%
3 maanden verandering	-99.97%
1 Jaar Verandering	-100.00%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Aug 16

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Aug 12

Kasey Rosado named interim CFO of Athersys

Aug 04

Athersys: Dead Man Walking

Jul 25

Athersys: Focus On Stroke

May 04

Athersys - Hero Or Zero Opportunity

Apr 18

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Jan 20

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Dec 30

Athersys: COVID-ARDS Is The Company's Most Important Target

Nov 25

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Aug 30

Athersys: Subgroup Analysis As A Masterstroke

Jul 29

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

May 28

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

Feb 27

Update On Athersys - Trying To Read Between The Lines

Feb 03

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

Feb 01

Athersys: Stem Cell Opportunity For Risk Tolerant Investors

Nov 12

Rendement voor aandeelhouders

	ATHX.Q	US Biotechs	US Markt
7D	0%	-0.2%	-0.4%
1Y	-100.0%	22.1%	34.1%

Rendement versus industrie: ATHX.Q underperformed the US Biotechs industry which returned 18.7% over the past year.

Rendement versus markt: ATHX.Q underperformed the US Market which returned 32.8% over the past year.

Prijsvolatiliteit

Is ATHX.Q's price volatile compared to industry and market?
ATHX.Q volatility
ATHX.Q Average Weekly Movement	6,647.3%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: ATHX.Q's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: ATHX.Q's weekly volatility has increased from 3185% to 6647% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	24	n/a	www.athersys.com

Athersys, Inc., een biotechnologiebedrijf, richt zich op onderzoeks- en ontwikkelingsactiviteiten op het gebied van regeneratieve geneeskunde. De klinische ontwikkelingsprogramma's zijn gericht op de behandeling van neurologische aandoeningen, hart- en vaatziekten, ontstekings- en immuunziekten, en long- en andere aandoeningen. Het belangrijkste platformproduct van het bedrijf omvat MultiStem celtherapie, een allogeen stamcelproduct voor de behandeling van patiënten die lijden aan neurologische schade als gevolg van een ischemische beroerte, evenals voor acuut ademnoodsyndroom, traumacomplicaties, HSC-transplantatieondersteuning en andere indicaties.

Athersys, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Athersys zich tot de beurswaarde?
ATHX.Q fundamentele statistieken
Marktkapitalisatie	US$6.17k
Inkomsten(TTM)	-US$37.51m
Inkomsten(TTM)	US$80.00k

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is ATHX.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ATHX.Q resultatenrekening (TTM)
Inkomsten	US$80.00k
Kosten van inkomsten	US$18.78m
Brutowinst	-US$18.69m
Overige uitgaven	US$18.81m
Inkomsten	-US$37.51m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.61
Brutomarge	-23,368.75%
Nettowinstmarge	-46,883.75%
Schuld/Eigen Vermogen Verhouding	-29.6%

Hoe presteerde ATHX.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

ATHX.Q Overzicht aandelen

Beloningen

Risicoanalyse

Athersys, Inc. Concurrenten

OTCPK:INFI.Q

US$90.0

OTCPK:OBSE.F

US$11.7k

OTCPK:MYMX

US$151.0

OTCPK:CMRA

US$30.0

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Recent updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought US$55k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Kasey Rosado named interim CFO of Athersys

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys: Dead Man Walking

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

Athersys: Focus On Stroke

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67